Physician profile
Lisa D Garbutt
NPI 1083755060
$6,753.00
in general payments reported to CMS, 2019-2025
27 companies · $956 in 2025
The $956 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $443 · 2021: $538 · 2022: $1,267 · 2023: $1,350 · 2024: $1,251 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,425.63 | 2019-2025 | Clareon, Argos, Eysuvis |
| Abbvie INC. | $593.62 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $512.65 | 2020-2025 | Cequa |
| Allergan, INC. | $485.27 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $457.18 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $445.68 | 2022-2025 | Miebo, Xiidra, Infuse |
| Rxsight INC | $385.80 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $311.82 | 2022-2025 | Tyrvaya |
| Glaukos Corporation | $238.93 | 2019-2022 | |
| Amgen INC. | $212.09 | 2024-2025 | Tepezza |
| Dompe US, INC. | $198.89 | 2021-2024 | Oxervate |
| Horizon Therapeutics Plc | $197.44 | 2019-2022 | |
| Sight Sciences, INC. | $186.94 | 2019-2024 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $157.56 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $155.41 | 2020-2024 | Tecnis Simplicity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $122.25 | 2019 | |
| Apellis Pharmaceuticals, INC. | $112.64 | 2023 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $96.96 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $94.93 | 2021-2023 | Flarex |
| Ani Pharmaceuticals, INC. | $78.74 | 2025 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $70.91 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $60.67 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $51.34 | 2020-2023 | Acthar |
| Ocular Therapeutix, INC. | $33.06 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $32.01 | 2019 | |
| New World Medical,INC. | $19.20 | 2019 | |
| Beaver-Visitec International, INC. | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Garbutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.